Skip to Main Content

Author Details

Austin Dulak
2008
19
17
PMIDPaper TitleJournal TitlePublished Year
37219538SRF617 Is a Potent Inhibitor of CD39 with Immunomodulatory and Antitumor Properties.2023
29808010Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition.Nat Med2018
30093730Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition.Nat Med2018
30036377BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors.PLoS One2018
29636547BRD4 facilitates replication stress-induced DNA damage response.Oncogene2018
28073847Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors.Clin Cancer Res2017
29245897Comparative analysis of primary <i>versus</i> relapse/refractory DLBCL identifies shifts in mutation spectrum.Oncotarget2017
27775716Potent and selective bivalent inhibitors of BET bromodomains.Nat Chem Biol2016
26781748Multi-omic measurement of mutually exclusive loss-of-function enriches for candidate synthetic lethal gene pairs.BMC Genomics2016
27573426AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.Mol Cancer Ther2016
24509200Comparison of cancer-associated genetic abnormalities in columnar-lined esophagus tissues with and without goblet cells.Annals of Surgery2014
24296828Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.Mol Cancer Ther2014
23525077Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.Nat Genet2013
23770567Mutational heterogeneity in cancer and the search for new cancer-associated genes.Nature2013
22751462Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis.Cancer Res2012
22400064Optical Imaging with a Cathepsin B Activated Probe for the Enhanced Detection of Esophageal Adenocarcinoma by Dual Channel Fluorescent Upper GI Endoscopy.Theranostics2012
21423210HGF-independent potentiation of EGFR action by c-Met.Oncogene2011
19826040microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells.Cancer Research2009
18645002Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis.Molecular Cancer Therapeutics2008
  • 1 - 19 of 19

Recommended Authors

Collaborators

Co-authored papers 8
Repare Therapeutics Inc.
Co-authored papers 4
Co-authored papers 4
Co-authored papers 4
Oncology R&D
Co-authored papers 4
Broad Institute
Co-authored papers 3
Present Address: Tempus Labs Inc.
Co-authored papers 3
Broad Institute of Massachusetts Institute of Technology and Harvard
Co-authored papers 3
Co-authored papers 3
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 3
Co-authored papers 2
The Broad Institute of Harvard and MIT
Co-authored papers 2
Case Western Reserve University School of Medicine
Co-authored papers 2
Vanderbilt-Ingram Cancer Center, Vanderbilt University
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
La Trobe Institute for Molecular Science, La Trobe University
Co-authored papers 2
Co-authored papers 2
Broad Institute of MIT and Harvard
Co-authored papers 2
Cystic Fibrosis Foundation
Co-authored papers 2
Novartis Institutes for BioMedical Research
Co-authored papers 2
Co-authored papers 2
Broad Institute of MIT and Harvard
Co-authored papers 2
Broad Institute of MIT and Harvard
Co-authored papers 2
Co-authored papers 2
Broad Institute of MIT and Harvard
Co-authored papers 2
Broad Institute of the Massachusetts Institute of Technology and Harvard
Co-authored papers 2
Co-authored papers 2
The Broad Institute of Harvard and MIT
Co-authored papers 2